CorMedix Derivative Suit Settled: Governance Reforms and a $3.9M Fee Request

summarizeSummary

CorMedix settled a derivative lawsuit over alleged FDA-related disclosure failures, agreeing to implement corporate governance reforms for at least 3.5 years. Plaintiffs' counsel will seek up to $3.9 million in fees, with a final court hearing set for September 23, 2026.

check_boxKey Events · Legal and Risk Events · CRMD

• Derivative Settlement Reached

  Consolidated derivative lawsuits alleging that officers and directors made misleading statements about manufacturing deficiencies that delayed FDA approval of DefenCath have been settled. The settlement requires adoption of corporate governance reforms for at least 3.5 years.

• Governance Reforms Mandated

  The mandated reforms include creating a management-level Disclosure Committee, enhancing the Nominating and Governance Committee's oversight of compliance, annual executive training on risk and FDA matters, director education requirements, and a strengthened whistleblower program.

• Plaintiffs' Counsel to Seek $3.9M in Fees

  Plaintiffs' attorneys intend to petition the court for up to $3.9 million in fees and expenses, plus service awards of up to $5,000 per plaintiff. Defendants reserve the right to oppose the fee request.

• Final Approval Hearing Set for September 23, 2026

  The U.S. District Court for the District of New Jersey will hold a hearing on September 23, 2026, to consider final approval of the settlement. Stockholders have until September 2, 2026, to object.

auto_awesomeAnalysis · CRMD · Life Sciences

A long-running derivative lawsuit over alleged disclosure failures that delayed FDA approval of DefenCath has been settled. Under the deal, CorMedix must adopt and maintain a slate of corporate governance reforms for at least 3.5 years — including a new Disclosure Committee, enhanced board oversight of compliance, and mandatory training for executives and directors. While the company admits no wrongdoing, the board acknowledges the litigation was a material factor in agreeing to the changes. Plaintiffs' counsel will seek up to $3.9 million in fees, a sum that could draw scrutiny at the September 23 final approval hearing. The settlement removes a legal overhang but comes with ongoing compliance obligations and a notable fee request.